Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 292 for:    warfarin AND anticoagulation

Warfarin Anticoagulation in Patients in Sub-Saharan Africa (War-PATH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03512080
Recruitment Status : Recruiting
First Posted : April 30, 2018
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
Professor Sir Munir Pirmohamed, University of Liverpool

Brief Summary:

This research programme aims to translate expertise in warfarin anticoagulation from resource-rich to low and middle income countries (LMIC)settings with the goal of improving patient health outcomes.

An observational study which will be used to develop warfarin dosing algorithms - the ultimate aim will be to ascertain whether these algorithms increase time in the therapeutic range, reduce bleeding and thrombotic risks, and clinic visits for International Normalised ratio (INR) monitoring. Two algorithms will be developed: the first will take into account clinical and geographical factors ("clinical algorithm"), while the second will also incorporate genetic factors in addition to the clinical and geographical factors ("genetic algorithm"). Patients will be recruited from sites in rural and urban Uganda, and in Cape Town, South Africa, to develop a clinical dosing algorithm. It is important to note that there is a wealth of literature data which will be used to define the clinical data that needs to be collected from these patients. To identify genetic factors in African patients, Genome-wide Association Study (GWAS) will be undertaken and any novel factors incorporated into the genetic algorithm - the percentage variation in warfarin dosing explained by the genetic algorithm will be compared with the clinical algorithm.


Condition or disease
Cardiovascular Diseases

Detailed Description:

This project focuses on an area unmet clinical need, oral anticoagulation, in patients with a variety of cardiovascular diseases. The investigators' ambition is to translate their internationally renowned expertise in warfarin anticoagulation into low and middle income country (LMIC) settings where it can significantly improve health. By working with policy makers, the investigators will provide the required evidence to allow national roll out of new practices, including the introduction of 1mg warfarin tablets as a quick win to improve dosing accuracy.

This National Institute of Health Research (NIHR) Global Research Group is a collaboration between the University of Liverpool and two low and middle income countries (LMICs), Uganda and South Africa. It will focus on a clinically important non-communicable disease area which requires the use of anticoagulation.

Anticoagulants, in particular warfarin, are used in these countries for the treatment of venous thromboembolism, valvular heart disease including rheumatic heart disease and prevention of strokes in patients with irregular heart rhythms (atrial fibrillation). Anticoagulation represents an unmet clinical need in Sub-Saharan Africa as patients either do not receive anticoagulation (because of difficulties in monitoring) or are poorly anticoagulated because of poor dosing guidelines. This results in potentially preventable morbidity and mortality which affects the poorer sectors of the population in particular. The investigators have extensive expertise in the United Kingdom and European Union of improving the use of warfarin through the development of novel dosing algorithms, which have now begun incorporating genetic factors.

By contrast, in the investigators' two collaborating partner countries, no locally validated warfarin dosing algorithms exist, even those which only take into account clinical factors. This results in haphazard dosing with the attendant risks of thrombotic or bleeding complications. In both countries, monitoring requires frequent clinic visits, incurring transport costs and missed work days. Patients are often co-infected with human immunodeficiency virus (HIV) and/or Tuberculosis, requiring multiple concomitant medicines which complicate warfarin dosing and dose adjustment.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: National Institute of Health Research (NIHR) Global Health Research Group on Warfarin Anticoagulation in Patients With Cardiovascular Disease in Sub-Saharan Africa
Actual Study Start Date : June 11, 2018
Estimated Primary Completion Date : July 31, 2019
Estimated Study Completion Date : May 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Group/Cohort
Stable International Normalised Ratio
Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).



Primary Outcome Measures :
  1. Identification of demographic, clinical and genetic factors in an African population that determine daily warfarin dosing requirements [ Time Frame: 1 year ]
    Completion of an audit to evaluate the current quality of anticoagulant services in Cape Town and rural and urban Uganda taking into account the indications, anticoagulant clinic set-up and quality of anticoagulation control.

  2. Development of a clinical algorithm taking into account patient factors, co-medications and underlying disease [ Time Frame: 3 years ]
    Recruitment of patients currently on warfarin will be undertaken to identify clinical and other non-genetic factors associated with poor anticoagulation control to enable development of a warfarin clinical dosing algorithm. Data on patients' age, weight, height, gender, co-morbidities, co-medications, socio-economic factors, warfarin dose history and quality of anticoagulant control (International Normalised ratio (INR) measurement history) will be obtained for the algorithm development.

  3. Development of a validated warfarin dosing algorithm taking into account both clinical and genetic factors [ Time Frame: 3+ years ]
    Evaluation of genes specific to the local African populations in Uganda and South Africa that can impact on anticoagulation control will be carried out, resulting in the development of a novel genetic dosing algorithm. In order to identify ethnic specific genetic factors, the investigators will undertake a Genome-wide Association Study (GWAS) on these patients, and any novel genetic factors will be incorporated into an improved dosing algorithm which will be compared with the original algorithm in terms of its ability to predict therapeutic dose.


Biospecimen Retention:   Samples With DNA
Blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Self-reported Black African ethnicity from Uganda and South Africa
Criteria

Inclusion Criteria:

  1. Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
  2. On a stable maintenance dose for two consecutive clinic visits within the last six months, and the INR was in the therapeutic range at each of those visits.
  3. Age over 18 years.
  4. Self-reported Black African ethnicity.
  5. Signed or witnessed written (witnessed thumbprint for illiterate participants) informed consent.

Exclusion Criteria:

  1. Patient unwilling to take part.
  2. Patient is, in the opinion of the investigator, not suitable to participate.
  3. Pregnant women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03512080


Contacts
Layout table for location contacts
Contact: Claire Hutchinson 44 151 794 5791 chutch@liverpool.ac.uk

Locations
Layout table for location information
South Africa
University of Cape Town Recruiting
Cape Town, South Africa
Contact: Karen Cohen         
Principal Investigator: Karen Cohen         
Sub-Investigator: Marc Blockman         
Uganda
Infectious Diseases Institute Recruiting
Kampala, Uganda
Contact: Catriona Waitt         
Sub-Investigator: Mohammed Lamorde         
Sub-Investigator: Christine Sekaggya         
Principal Investigator: Catriona Waitt         
Sponsors and Collaborators
University of Liverpool
Investigators
Layout table for investigator information
Principal Investigator: Munir Pirmohamed University of Liverpool

Publications:

Layout table for additonal information
Responsible Party: Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine and National Health Service (NHS) Chair of Pharmacogenetics, University of Liverpool
ClinicalTrials.gov Identifier: NCT03512080     History of Changes
Other Study ID Numbers: UoL001324
First Posted: April 30, 2018    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Professor Sir Munir Pirmohamed, University of Liverpool:
Warfarin
Anticoagulation
Clinical Dosing Algorithm
Genetic Dosing Algorithm
International Normalised Ratio
Uganda
Cape Town
Cardiovascular Disease
Genome-wide Association Study
Stratified Medicine
Pharmacogenetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Warfarin
Anticoagulants